

All Wales Medicines Strategy Group

Annual Report 2021–2022:

Supplement - accessible versions of graphs and tables

“Supporting prudent prescribing to obtain the best outcomes from medicines for patients in Wales”

Delivering the recommendations of AWMSG's five-year strategy 2018–2023

AWMSG works with partners to deliver the recommendations of the Medicines Strategy for Wales 2018–2023 to improve the safe use of medicines, promote best practice and optimise the use of medicines to benefit the people of Wales. The table below provides an update on the work undertaken to implement the recommendations during the reporting period 1 April 2021 to 31 March 2022. [The AWMSG five-year strategy 2018–2023](#) can be viewed on the AWTTC website.

Work undertaken to implement the recommendations during April 2021 to March 2022		
Title	Type of publication	Strategy recommendation
Medicines Optimisation Framework	Medicines optimisation resource	4.3 Improving prescribing and medicines optimisation within NHS Wales
NHS Wales GP Cluster Prescribing Leads Forum proposal – the Royal College of General Practitioners webinar January 2022	Report and presentation	2.1 Workforce development
AWTTC: Supporting implementation of advanced therapy medicinal products in NHS Wales	Report	4.6 Health technology assessment – ensuring the appraisal process is reviewed and meets the developing needs of NHS Wales
AWMSG: 18 years' experience of a national medicines optimisation committee. Haines et al. British Journal of Clinical Pharmacology 2021; 87(10): 3961-3970.	Research publication	4.3 Improving prescribing and medicines optimisation within NHS Wales
Appraisal of biosimilar medicines report	Report	4.7 Wales Patient Access Scheme – ensuring NHS Wales recoups any financial discounts
Initial clinical management of adult smokers in secondary care guideline	Medicines optimisation resource	2.1 Workforce development 2.3 Safe medication systems 4.2 Nationally available medicines list 4.3 Improving prescribing and medicines optimisation within NHS Wales

Work undertaken to implement the recommendations during April 2021 to March 2022

Title	Type of publication	Strategy recommendation
<u>Material to support appropriate prescribing of hypnotics and anxiolytics across Wales (2021 update)</u>	Medicines optimisation resource	1.3 Ensuring fair and equitable provision of healthcare 2.1 Workforce development 2.3 Safe medication systems 3.3 Medication review 3.4 Medicine-related harm 4.3 Improving prescribing and medicines optimisation within NHS Wales
<u>National Prescribing Indicators 2021–2022: educational module</u>	Medicines optimisation resource	2.1 Workforce development
<u>All Wales advice on sodium-glucose cotransporter-2 inhibitors in type 2 diabetes and cardiovascular disease</u>	Medicines optimisation resource	2.1 Workforce development 2.3 Safe medication systems 4.3 Improving prescribing and medicines optimisation within NHS Wales
<u>Tramadol educational resources (2021 review)</u>	Medicines optimisation resource	2.1 Workforce development 2.3 Safe medication systems 3.4 Medicine-related harm 4.3 Improving prescribing and medicines optimisation within Wales
Pharmacogenetics in Wales	Report	3.4 Medicine-related harm
AWMSG Communication and Engagement Strategy	Report	1.1 Partnership with the public 2.1 Workforce development 4.3 Improving prescribing and medicines optimisation within NHS Wales
<u>All Wales chronic obstructive pulmonary disease management and prescribing guideline (2021 update)</u>	Medicines optimisation resource	2.1 Workforce development 4.2 Nationally available medicines list 4.3 Improving prescribing and medicines optimisation within NHS Wales 4.8 Using data to improve patient outcomes

Work undertaken to implement the recommendations during April 2021 to March 2022


Title	Type of publication	Strategy recommendation
All Wales adult asthma management and prescribing guideline (2021 update)	Medicines optimisation resource	2.1 Workforce development 4.2 Nationally available medicines list 4.3 Improving prescribing and medicines optimisation within NHS Wales 4.8 Using data to improve patient outcomes
National Prescribing Indicators 2022–2023	Medicines optimisation resource	4.3 Improving prescribing and medicines optimisation within NHS Wales 4.5 National Prescribing Indicators
National Prescribing Indicators 2022–2023 – Supporting information for prescribers and healthcare professionals	Medicines optimisation resource	2.1 Workforce development
National Prescribing Indicators 2021–2022: Quarterly reports	Report	4.3 Improving prescribing and medicines optimisation within NHS Wales 4.5 National Prescribing Indicators
AWMSG Acknowledgement: Heart failure in Wales – A parallel approach	Medicines optimisation resource (Acknowledgement)	2.1 Workforce development 4.3 Improving prescribing and medicines optimisation within NHS Wales
AWMSG Acknowledgement: Antimicrobial wound dressings: Statement, recommendations and guidance	Medicines optimisation resource (Acknowledgement)	2.1 Workforce development 4.3 Improving prescribing and medicines optimisation within NHS Wales
AWMSG Acknowledgement: Cellulitis guidelines for people with lymphoedema/chronic oedema in NHS Wales	Medicines optimisation resource (Acknowledgement)	2.1 Workforce development 4.3 Improving prescribing and medicines optimisation within NHS Wales
Primary care antimicrobial guidelines	Medicines optimisation resource	2.1 Workforce development 2.3 Safe medication systems 4.3 Improving prescribing and medicines optimisation within NHS Wales 4.5 National Prescribing Indicators

Work undertaken to implement the recommendations during April 2021 to March 2022


Title	Type of publication	Strategy recommendation
Clinical Effectiveness Prescribing Programme national audit – focus on antibiotic prescribing	Medicines optimisation resource	2.1 Workforce development 2.3 Safe medication systems 4.3 Improving prescribing and medicines optimisation within NHS Wales 4.5 National Prescribing Indicators
Management of <i>Clostridioides difficile</i> infection in Wales	Medicines optimisation resource	2.1 Workforce development 2.3 Safe medication systems 4.3 Improving prescribing and medicines optimisation within NHS Wales
Management of recurrent symptomatic urinary tract infection in adult women	Medicines optimisation resource	2.1 Workforce development 2.3 Safe medication systems 4.3 Improving prescribing and medicines optimisation within NHS Wales
All Wales advice on oral anticoagulation in non-valvular atrial fibrillation (2022 update)	Medicines optimisation resource	2.1 Workforce development 4.2 Nationally available medicines list 4.3 Improving prescribing and medicines optimisation within NHS Wales
NHS Wales decarbonisation dashboard and Inhaler carbon footprint reports	Medicines optimisation resource and reports	4.3 Improving prescribing and medicines optimisation within NHS Wales

Health Technology Assessment

Number of medicines recommended and not recommended




Type of submission for appraisal



*Process introduced in 2021

**Reassessment of emtricitabine/tenofovir disoproxil

Appraisals with a Patient Access Scheme



Membership

AWMSG

Post	Member	Deputy
Chair	Prof Iolo Doull	
Consultant in Public Health Medicine	Prof Stephen Monaghan	Awaiting nomination
Welsh Health Specialised Services Committee	Ms Eleri Schiavone	Dr Helen Fardy
Health Economist	Prof Dyfrig Hughes	Prof Deborah Fitzsimmons Prof Pippa Anderson
ABPI (Wales)	Ms Kate Parrish Mr Tommy Price Mr Farhan Mughal	Attendance is rotated between the three named individuals
Lay representative	Mr Cliff Jones	Awaiting nomination
Lay representative	Ms Claire James	Awaiting nomination
Community Pharmacist	Mr Stefan Fec (to February 2022)	Mr Dylan Jones
Medical Director	Dr Jim McGuigan	Awaiting nomination
GP with prescribing lead role	Dr Jeremy Black	Awaiting nomination
Managed Sector Pharmacist	Ms Alison Hughes	Ms Rafia Jamil
Managed Sector Pharmacist	Mr John Terry	Mr Stuart Rees
Director of Finance	Mr Hywel Pullen	Mr James Leaves
Senior Nurse	Mrs Louise Williams (to February 2022)	Mrs Mandy James
Other healthcare professions eligible to prescribe not already represented	Mr Aled Falvey (to August 2021) Mrs Cathy Wynne (from September 2021)	Mrs Cathy Wynne (to August 2021) Mr Karl Jackson (from September 2021)
Clinical Pharmacologist	Dr Balwinder Bajaj (to January 2022) Dr Alison Thomas (from February 2022)	Dr Alison Thomas (to January 2022) Dr Manjeet Singh (from February 2022)
Hospital Consultant	Dr Samantha Cox	Dr Satish Kumar (to January 2022)

AWPAG

Post and discipline	Member	Health board/trust	Alternate
Chair, Consultant Clinical Pharmacologist	Dr Laurence Gray	Cardiff and Vale	Mrs Clare Clement
Doctor from each health board reflecting different roles			
General Practitioner	Dr Rebecca McGee	Aneurin Bevan	Dr David Pyle (Powys)
Hospital Consultant/General Practitioner	Awaiting nomination	Betsi Cadwaladr	
Hospital Consultant/General Practitioner	Awaiting nomination	Cwm Taf Morgannwg	
Hospital Consultant	Dr Laurence Gray	Cardiff and Vale	
General Practitioner	Dr Richard Brown	Hywel Dda	
Hospital Consultant	Dr Anders Skarsten (to Aug 21)	Powys	
General Practitioner	Dr Phil Cox	Swansea Bay	
Hospital Consultant	Awaiting nomination	Velindre	
Pharmacist from each health board/trust reflecting different roles			
Prescribing Advisor	Mr Hywel Jones	Aneurin Bevan	Ms Emily Knight
Pharmacist	Awaiting nomination	Betsi Cadwaladr	Mr Ben Woodhouse
Pharmacist	Mrs Clare Clement	Cardiff and Vale	Miss Karen May (to Mar 22)
Pharmacist	Mrs Helen Davies Ms Kate Spittle (to Aug 21)	Cwm Taf Morgannwg	Mrs Avril Tucker
Prescribing Advisor	Mrs Hazel Hopkins	Hywel Dda	Mrs Sue Beach Ms Jenny Pugh-Jones
Community Pharmacist	Mr Dylan Jones (to Feb 22)	Powys	Mr Adrian Byrne Mr Sudhir Sehrawat (Community)
Pharmacist	Mr Darren Smith	Swansea Bay	Awaiting nomination
Chief Pharmacist	Mrs Bethan Tranter	Velindre	Mrs Sophie Harding

Post and discipline	Member	Health board/trust	Alternate
Medicines Safety Pharmacist			
	Dr Lynette James	All Wales	
Lay member			
	Mr David Barnard		Mr Alan Meudell
Healthcare professional eligible to prescribe			
	Mrs Amy Williams Mr Robert Caine (to Jan 22)		Awaiting nomination
Nurse			
	Mrs Sarah Davies		Ms Sabrina Owen (to Mar 22)
Public Health Wales			
	Ms Rosemary Allgeier		Mrs Sian Evans
ABPI Wales Industry Group			
	Ms Sue Knights		Ms Rachel Jenkins
Non-voting members			
Director Association of the British Pharmaceutical Industry Wales	Dr Rick Greville		
Director British Generic Manufacturers Association	Mr Paul Fleming		Ms Carol Blount
Welsh Government	To be notified of representation before each meeting		
AWTTC Board Member and AWMSG Representative	To be notified of representation before each meeting		

NMG

Post	Member	Deputy
Chair	Dr James Coulson	
Vice Chair	Dr Emma Mason	
Pharmacist 1	Mr Alan Clatworthy (from May 2022) Ms Suzanne Davies (to March 2022)	Eleri Phillips
Pharmacist 2	Mrs Sue Beach	Nomination received
Pharmacist 3	Mrs Teena Grenier	Awaiting nomination
Doctor 1 - Clinical Pharmacologist	Dr Manjeet Singh	Awaiting nomination
Doctor 2 - Hospital Consultant	Awaiting nomination	Awaiting nomination
Doctor 3 - General Practitioner	Dr Chalini Lankage (from April 2022)	Dr Avkash Das Jain
Professions allied to medicine or eligible to prescribe	Mr Karl Jackson Ms Cathy Wynne (to October 2021)	Awaiting nomination
Public Health/Epidemiologist	Awaiting nomination	Awaiting nomination
Health Economist	Professor Deborah Fitzsimmons	Dr Catrin Plumpton
ABPI Member	Mr Steven Lister Mr Sandeep Kiri Ms Holly Cranmer	Attendance is rotated between the three named individuals
Welsh Health Specialised Services Committee	Dr Andrew Champion	Dr Sian Lewis

Post	Member	Deputy
Lay Member	Mr William Anthony Esmond (from March 2022) Mr Christopher Palmer (to March 2022) Awaiting nomination	Awaiting nomination
Nurse	Mr Neil Thomas	Mr Andrew Davies (from April 2022) Mrs Susan Newport Dr Carolyn Middleton (to July 2021)



AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thoicsicoleg Cymru Gyfan

Published by:

All Wales Therapeutics and Toxicology Centre
The Routledge Academic Centre
University Hospital Llandough
Vale of Glamorgan
CF64 2XX

On behalf of the All Wales Medicines Strategy Group

All enquiries should be directed to:

Mrs Ruth Lang
Senior Liaison Manager
Email: awttc@wales.nhs.uk
Telephone: 029 218 26900

Please note information in this document is correct at the time of print but may be subject to change.
For latest information, please visit awttc.nhs.wales (English) and cttcg.gig.cymru (Welsh). English Twitter account [@AWTTComms](https://twitter.com/AWTTComms); Welsh Twitter account [@AWTTcymraeg](https://twitter.com/AWTTcymraeg).